drugset
drugset / Trial / NCT04026711

MitoQ for the Treatment of Metabolic Dysfunction in Asthma

NCT04026711 ↗

Phase 1 Completed 47 enrolled University of Vermont Duke University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma. The intervention is Mitoquinol (MitoQ) versus placebo. The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in obese patients with asthma.

Timeline

Start
2020-01-01
Primary completion
2024-03-31
Completion
2024-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mitoquinol Small molecule 40 mg —

Indications

asthma obesity disorder